Bacterial meningitis: The impact of vaccination

CNS Drugs

Volumn 21, Issue 5, 2007, Pages 355-366

  Makwana, Nick ^a   Riordan, F Andrew I ^a  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE PLUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA TOXOID; DRUG CARRIER; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES VACCINE; MENINGOCOCCUS AYCW VACCINE; MENINGOCOCCUS VACCINE; NEISSERIA MENINGITIDIS PROTEIN; OUTER MEMBRANE PROTEIN; PLACEBO; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE POLYRIBOSYLRIBITOL PHOSPHATE; POLYSACCHARIDE VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DEVELOPED COUNTRY; DIPHTHERIA; DRUG COST; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE TYPE B; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOPROPHYLAXIS; INFECTION SENSITIVITY; MEASLES; MEMORY CELL; MENINGOCOCCOSIS; META ANALYSIS; MORBIDITY; MORTALITY; NEISSERIA MENINGITIDIS; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; T LYMPHOCYTE; TETANUS; TUBERCULOSIS; VACCINATION;

ANIMALS; BACTERIAL VACCINES; HAEMOPHILUS VACCINES; HUMANS; MENINGITIS, BACTERIAL; MENINGITIS, HAEMOPHILUS; MENINGITIS, MENINGOCOCCAL; MENINGITIS, PNEUMOCOCCAL; VACCINATION; VACCINES, CONJUGATE;

EID: 34247869036     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721050-00001     Document Type: Review

References (113)

1. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13 (2): 302-17
2. Hausdorff W. Haemophilus, meningococcus and pneumococcus: comparative epidemiologic patterns of disease. Int J Clin Pract 2001; Suppl. 118: 2-4
3. Oostenbrink R, Maas M, Moons KG, et al. Sequelae after bacterial meningitis in childhood. Scand J Infect Dis 2002; 34 (5): 379-82
4. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336 (10): 708-16
5. Ada G. Vaccines and vaccination. N Engl J Med 2001; 345 (14): 1042-53
6. Goldblatt D. Recent developments in bacterial conjugate vaccines. J Med Microbiol 1998; 47 (7): 563-7
7. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vacine era. JAMA 1993; 269 (2): 221-6
8. Levine OS, Schwartz B, Pierce N, et al. Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: cur rent status and priority actions. Pediatr Infect Dis J 1998; 17 (9 Suppl.): S95-113
9. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 1999; 18 (6): 543-51
10. Salisbury D. Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Paediatr Child Health 2001; 37 (5): S34-6
11. Shinefield H. Pneumococcal conjugate vaccine and ongoing lessons. Int J Clin Pract 2001; Suppl. 118: 23-5
12. Department of Health. Salisbury DM, Begg NT, editors. Immunisation against infectious disease. London: HMSO, 1996
13. Booy R, Hodgson SA, Slack MP, et al. Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91). Arch Dis Child 1993; 69 (2): 225-8
14. Bijlmer HA, van Alphen L, Greenwood BM, et al. The epidemiology of Haemophilus influenzae meningitis in children under five years of age in The Gambia, West Africa. J Infect Dis 1990; 161 (6): 1210-5
15. Global Programme for Vaccines and Immunization (GPV), World Health Organization. The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 1998; 73 (10): 64-71
16. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113 (2): 163-74
17. The impact of Haemophilus influenzae immunisation on inva sive infection in children. Commun Dis Rep CDR Wkly 1993; 3 (51): 231
18. Booy R, Heath PT, Slack MP, et al. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 1997; 349 (9060): 1197-202
19. Granoff DM, Anderson EL, Osterholm MT, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992; 121 (2): 187-94
20. Decker MD, Edwards KM, Bradley R, et al. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120 (2 Pt 1): 184-9
21. Kayhty H, Eskola J, Peltola H, et al. Antibody responses to four Haemophilus influenzae type b conjugate vaccines. Am J Dis Child 1991; 145 (2): 223-7
22. Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992; 267 (11): 1489-94
23. Englund JA, Glezen WP. Maternal immunization with Haemophilus influenzae type b vaccines in different populations. Vaccine 2003; 21 (24): 3455-9
24. Granoff DM, Holmes SJ, Osterholm MT, et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis 1993; 168 (3): 663-71
25. Eskola J, Ward J, Dagan R, et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999; 354 (9195): 2063-8
26. Eskola J, Peltola H, Takala AK, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 1987; 317 (12): 717-22
27. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants [published erratum appears in Lancet 1997; 350 (9076): 524]. Lancet 1997; 349 (9060): 1191-7
28. Booy R, Moxon ER, MacFarlane JA, et al. Efficacy of Haemophilus influenzae type B conjugate vaccine in Oxford region. Lancet 1992; 340 (8823): 847
29. Galil K, Singleton R, Levine OS, et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis 1999; 179 (1): 101-6
30. Swingler G, Fransman D, Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type b infections. Cochrane Database Syst Rev 2003; (4): CD001729
31. Peltola H, Kallio MJ, Unkila-Kallio L. Reduced incidence of septic arthritis in children by Haemophilus influenzae type-b vaccination: implications for treatment. J Bone Joint Surg Br 1998; 80 (3): 471-3
32. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 1998; 17 (9 Suppl.): S117-22
33. Peltola H. Haemophilus influenzae type b disease and vaccination in Europe: lessons learned. Pediatr Infect Dis J 1998; 17 (9 Suppl.): S126-32
34. Laval CA, Pimenta FC, de Andrade JG, et al. Progress towards meningitis prevention in the conjugate vaccines era. Braz J Infect Dis 2003; 7 (5): 315-24
35. Dickinson FO, Perez AE, Galindo MA, et al. Impact of vaccination against Haemophilus influenzae type b in Cuba [in Spanish]. Rev Panam Salud Publica 2001; 10 (3): 169-73
36. Ribeiro GS, Reis JN, Cordeiro SM, et al. Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J Infect Dis 2003; 187 (1): 109-16
37. Agudelo CI, Munoz N, De la Hoz F. Rapid assessment of the impact of Haemophilus influenzae vaccine serotype b in Colombia [in Spanish]: Public Health Laboratories. Rev Panam Salud Publica 2000; 8 (3): 181-4
38. Diaz JM, Catalan L, Urrutia MT, et al. Trends of etiology of acute bacterial meningitis in Chilean children from 1989 to 1998: impact of the anti-H influenzae type b vaccine [in Spanish]. Rev Med Chil 2001; 129 (7): 719-26
39. Barbour ML, Mayon-White RT, Coles C, et al. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 1995; 171 (1): 93-8
40. Hviid A, Melbye M. Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine. Vaccine 2004; 22 (3-4): 378-82
41. Takala AK, Santosham M, Meido-Hill J, et al. Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children. Pediatr Infect Dis J 1993; 12 (7): 593-9
42. Zhou F, Bisgard KM, Yusuf HR, et al. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics 2002; 110 (4): 653-61
43. Trollfors B. Cost-benefit analysis of general vaccination against Haemophilus influenzae type b in Sweden. Scand J Infect Dis 1994; 26 (5): 611-4
44. Livartowski A, Boucher J, Detournay B, et al. Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France. Vaccine 1996; 14 (6): 495-500
45. Peltola H, Salo E, Saxen H. Incidence of Haemophilus influenzae type b meningitis during 18 years of vaccine use: observational study using routine hospital data. BMJ 2005; 330 (7481): 18-9
46. Hanna JN. Impact of Haemophilus influenzae type b (Hib) vaccination on Hib meningitis in children in Far North Queensland, 1989 to 2003. Commun Dis Intell 2004; 28 (2): 255-7
47. Ruocco G, Curto S, Savio M, et al. Vaccination against Haemophilus influenzae type b in Uruguay: experience and impact [in Spanish]. Rev Panam Salud Publica 1999; 5 (3): 197-9
48. Dawson KG, Emerson JC, Burns JL. Fifteen years of experience with bacterial meningitis. Pediatr Infect Dis J 1999; 18 (9): 816-22
49. Garpenholt O, Silfverdal SA, Hugosson S, et al. The impact of Haemophilus influenzae type b vaccination in Sweden. Scand J Infect Dis 1996; 28 (2): 165-9
50. Teare EL, Fairley CK, White J, et al. Efficacy of Hib vaccine. Lancet 1994; 344 (8925): 828-9
51. van Alphen L, Spanjaard L, van der Ende A, et al. Predicted disappearance of Haemophilus influenzae type b meningitis in Netherlands. Lancet 1994; 344 (8916): 195
52. Zielen S, Ahrens P, Hofmann D. Efficacy of Hib vaccine. Lancet 1994; 344 (8925): 828
53. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340 (8819): 592-4
54. Heath PT, Bowen-Morris J, Griffiths D, et al. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child 1997; 77 (6): 488-92
55. Bell F, Martin A, Blondeau C, et al. Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation. Arch Dis Child 1996; 75 (4): 298-303
56. Bell F, Heath P, Shackley F, et al. Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T). Vaccine 1998; 16 (6): 637-42
57. McVernon J, Moxon R, Heath P, et al. Haemophilus influenzae type b epiglottitis: article gives timely lesson [letter]. BMJ 2003; 326 (7383): 284
58. Ramsay ME, McVernon J, Andrews NJ, et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188 (4): 481-5
59. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000; 284 (18): 2334-40
60. Madore DV, Johnson CL, Phipps DC, et al. Safety and immunogenicity of Hib oligosaccharide-CRM197 conjugate vaccine in infants aged 15-23 months. Pediatrics 1990; 86: 527-34
61. Goldblatt D, Miller E, McCloskey N, et al. Immunological response to conjugate vaccines in infants: follow up study. BMJ 1998; 316 (7144): 1570-1
62. McVernon J, Andrews N, Slack MP, et al. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361 (9368): 1521-3
63. McVernon J, Howard AJ, Slack MP, et al. Long-term impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the United Kingdom. Epidemiol Infect 2004; 132 (4): 765-7
64. McVernon J, Johnson PD, Pollard AJ, et al. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child 2003; 88 (5): 379-83
65. Heath PT, Ramsay ME. Haemophilus influenzae type b vaccine-booster campaign. BMJ 2003; 326 (7400): 1158-9
66. Peltola H. Need for Haemophilus influenzae type b vaccination in Asia as evidenced by epidemiology of bacterial meningitis. Pediatr Infect Dis J 1998; 17 (9 Suppl.): S148-51
67. World Health Organisation. Expert review of a tool for rapidly assessing Haemophilus influenzae type b (Hib) disease burden [online]. Available from URL: http://www.who.int/vaccinesdocuments/DocsPDF01/www.604.pdf [Accessed 2007 Jan 10]
68. Peltola H. Burden of meningitis and other severe bacterial infections of children in Africa: implications for prevention. Clin Infect Dis 2001; 32 (1): 64-75
69. Vaccine fund progress report [online]. Available from URL: http://www.gavialliance.org [Accessed 2007 Apr 2]
70. Wenger JD, DiFabio J, Landaverde JM, et al. Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four 'newly adopting' countries. Vaccine 1999; 18 (7-8): 736-42
71. Henrichsen J. Typing of Streptococcus pnemoniae: past, present and future. Am J Med 1999; 107 (1A): 50-4S
72. Mbelle N, Huebner RE, Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180 (4): 1171-6
73. Murdoch C, Lakshman R, Burkinshaw R, et al. Effect of heptavalent conjugate pneumococcal vaccine in infancy and booster polysaccharide vaccine at 13 months on nasopharyngeal carriage of S. pneumoniae in children aged 2-4 years [abstract]. Clin Infect Dis 2001; 33: 1148
74. Dagan R, Fraser D. Conjugate pneumococcal vaccine and antibiotic-resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity. Pediatr Infect Dis J 2000; 19 (5 Suppl.): S79-87
75. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344 (6): 403-9
76. Gherardi G, Inostrozo JS, O'Ryan M, et al. Genotypic survey of recent beta-lactam-resistant pneumococcal nasopharyngeal isolates from asymptomatic children in Chile. J Clin Microbiol 1999; 37 (11): 3725-30
77. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348 (18): 1737-46
78. Greenwood B. The epidemiology of pneumococcal infection in children in the developing world. Philos Trans R Soc Lond B Biol Sci 1999; 354 (1384): 777-85
79. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343 (26): 1917-24
80. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use (Pt I). Clin Infect Dis 2000; 30 (1): 100-21
81. Hausdorff WP, Bryant J, Kloek C, et al. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use (Pt II). Clin Infect Dis 2000; 30 (1): 122-40
82. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19 (3): 187-95
83. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349 (14): 1341-8
84. Mulholland K. Strategies for the control of pneumococcal diseases. Vaccine 1999; 17 Suppl. 1: S79-84
85. Klugman KP. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect Dis 2001; 1 (2): 85-91
86. Black SB, Shinefield HR, Hansen J, et al. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001; 20 (12): 1105-7
87. Dagan R, Sikuler-Cohen M, Zamir O, et al. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr Infect Dis J 2001; 20 (10): 951-8
88. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174 (6): 1271-8
89. Schwartz B, Moore PS, Broome CV. Global epidemiology of meningococcal disease. Clin Microbiol Rev 1989; 2 Suppl.: S118-24
90. Ramsay ME, Kaczmarski E, Rush M, et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev 1997; 7 (4): R49-54
91. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV: immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969; 129 (6): 1367-84
92. Ramsay ME, Andrews N, Kaczmarski EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357 (9251): 195-6
93. Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health 2002; 5 (3): 220-5
94. Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 2002; 324 (7341): 809-14
95. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359 (9320): 1829-31
96. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364 (9431): 365-7
97. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326 (7385): 365-6
98. Cartwright K, Noah N, Peltola H. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European Advisory Board meeting, Vienna, Austria, 6-8 October, 2000. Vaccine 2001; 19 (31): 4347-56
99. Connolly M, Noah N. Is group C meningococcal disease increasing in Europe: a report of surveillance of meningococcal infection in Europe 1993-6. European Meningitis Surveillance Group. Epidemiol Infect 1999; 122 (1): 41-9
100. Segal S, Pollard AJ. The future of meningitis vaccines. Hosp Med 2003; 64 (3): 161-7
101. Baker MG, Martin DR, Kieft CE, et al. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health 2001; 37 (5): S13-9
102. Pollard AJ, Maiden MC. Epidemic meningococcal disease in sub-Saharan Africa: towards a sustainable solution? Lancet Infect Dis 2003; 3 (2): 68-70
103. Lingappa JR, Al-Rabeah AM, Hajjeh R, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000 [published erratum appears in Emerg Infect Dis 2003; 9 (8): 1028]. Emerg Infect Dis 2003; 9 (6): 665-71
104. Pollard AJ, Scheifele D. Meningococcal disease and vaccination in North America. J Paediatr Child Health 2001; 37 (5): S20-7
105. Rennels M, King Jr J, Ryall R, et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23 (5): 429-35
106. Campbell JD, Edelman R, King Jr JC, et al. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002; 186 (12): 1848-51
107. Rennels M, King Jr J, Ryall R, et al. Dose escalation, safety and immunogenicity study of a tetravalent meningococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr Infect Dis J 2002; 21 (10): 978-9
108. Granoff DM, Harris SL. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2004; 23 (6): 490-7
109. Granoff DM, Morgan A, Welsch JA. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2005; 24 (2): 132-6
110. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR Recomm Rep 2005; 54 (RR-7): 1-21
111. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006; 19 (1): 142-64
112. Pan American Health Organisation. Meningococcal conjugate vaccines for Africa. Washington, DC: Pan American Health Organisation, 2002
113. Buttery JP, Riddell A, McVernon J, et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 2005; 293 (14): 1751-8